Key Points
- Major shareholder TPG GP A sold 13.64 million LifeStance shares for approximately $144.9 million at an average price of $10.62, reducing its position by 12.21% while retaining about 98.1 million shares.
- LifeStance reported a quarterly earnings and revenue beat, with EPS of $0.06 versus the $0.03 consensus and revenue up 26.1% year over year to $435.35 million.
- LFST shares traded near a 52-week high after rising 6.3%, supported by largely positive analyst sentiment; the stock has a “Moderate Buy” consensus rating and an average price target of $11.62.
LifeStance Health Group, Inc. (NASDAQ:LFST - Get Free Report) CTO Vukasin Paunovich sold 44,394 shares of the business's stock in a transaction on Monday, August 10th. The shares were sold at an average price of $10.85, for a total transaction of $481,674.90. Following the sale, the chief technology officer directly owned 247,446 shares in the company, valued at $2,684,789.10. This trade represents a 15.21% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.
LifeStance Health Group Stock Performance
Shares of LFST stock opened at $12.23 on Thursday. The firm has a market capitalization of $4.74 billion, a price-to-earnings ratio of 94.08 and a beta of 1.14. The company has a debt-to-equity ratio of 0.18, a current ratio of 1.38 and a quick ratio of 1.38. The business has a fifty day moving average of $10.19 and a 200 day moving average of $8.16. LifeStance Health Group, Inc. has a 1 year low of $4.77 and a 1 year high of $12.43.
LifeStance Health Group (NASDAQ:LFST - Get Free Report) last released its earnings results on Thursday, August 6th. The company reported $0.06 EPS for the quarter, topping analysts' consensus estimates of $0.03 by $0.03. The firm had revenue of $435.35 million during the quarter, compared to the consensus estimate of $414.58 million. LifeStance Health Group had a return on equity of 3.39% and a net margin of 3.19%.The company's revenue was up 26.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.01) earnings per share. As a group, research analysts expect that LifeStance Health Group, Inc. will post 0.15 earnings per share for the current year.
Institutional Investors Weigh In On LifeStance Health Group
Several hedge funds have recently bought and sold shares of LFST. Larson Financial Group LLC grew its stake in shares of LifeStance Health Group by 19,952.6% during the 4th quarter. Larson Financial Group LLC now owns 3,810 shares of the company's stock worth $27,000 after purchasing an additional 3,791 shares during the period. KBC Group NV acquired a new position in shares of LifeStance Health Group in the 1st quarter valued at $29,000. EverSource Wealth Advisors LLC lifted its stake in shares of LifeStance Health Group by 359.1% in the 1st quarter. EverSource Wealth Advisors LLC now owns 6,909 shares of the company's stock valued at $44,000 after purchasing an additional 5,404 shares during the period. Bayesian Capital Management LP acquired a new position in shares of LifeStance Health Group in the 2nd quarter valued at $52,000. Finally, PNC Financial Services Group Inc. boosted its holdings in LifeStance Health Group by 615.3% during the first quarter. PNC Financial Services Group Inc. now owns 9,285 shares of the company's stock worth $59,000 after buying an additional 7,987 shares in the last quarter. Hedge funds and other institutional investors own 85.50% of the company's stock.
Wall Street Analysts Forecast Growth
LFST has been the topic of several recent research reports. Wall Street Zen downgraded shares of LifeStance Health Group from a "strong-buy" rating to a "buy" rating in a report on Saturday, July 25th. JPMorgan Chase & Co. raised their target price on shares of LifeStance Health Group from $8.00 to $9.00 and gave the stock a "neutral" rating in a report on Thursday, May 14th. Zacks Research downgraded shares of LifeStance Health Group from a "strong-buy" rating to a "hold" rating in a research report on Monday, July 13th. Canaccord Genuity Group upped their price target on shares of LifeStance Health Group from $11.00 to $13.00 and gave the company a "buy" rating in a report on Tuesday, July 21st. Finally, Weiss Ratings raised shares of LifeStance Health Group from a "hold (c-)" rating to a "hold (c)" rating in a report on Tuesday. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and four have assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $11.62.
View Our Latest Stock Analysis on LifeStance Health Group
Key LifeStance Health Group News
Here are the key news stories impacting LifeStance Health Group this week:
- Positive Sentiment: Analyst support remains strong. Morgan Stanley reaffirmed its Buy rating, while BTIG Research recently raised its price target from $15 to $16 and maintained a Buy rating. These actions reinforce the bullish view of LifeStance’s growth prospects. Morgan Stanley Reaffirms Their Buy Rating on LifeStance Health Group
- Positive Sentiment: LifeStance’s earnings momentum is supporting the stock. The company recently exceeded quarterly earnings and revenue expectations, with revenue rising 26.1% year over year. Zacks also upgraded LFST to a Rank #2 (Buy), citing improving earnings prospects. LifeStance Health Upgraded to Buy
- Positive Sentiment: Investor interest has pushed LFST to a new 52-week high. The move reflects strong recent momentum and growing optimism about the company’s fundamentals, although the elevated valuation increases the importance of continued execution. LifeStance Health Group Sets New 1-Year High
- Neutral Sentiment: LifeStance released survey findings highlighting demand for mental-health services integrated into perimenopause and menopause care. The announcement supports awareness of a potential growth niche but does not directly change financial guidance. LifeStance Survey on Menopause Care
- Negative Sentiment: Several insiders reduced their holdings. Major shareholder TPG GP A sold 13.64 million shares for approximately $144.9 million, while the COO and CTO sold shares worth about $519,845 and $481,675, respectively. Although each seller retained a substantial position, the transactions may raise concerns about profit-taking and near-term selling pressure. LifeStance Insider Sale Filing
LifeStance Health Group Company Profile
(
Get Free Report)
LifeStance Health Group (NASDAQ:LFST) is a leading provider of outpatient mental health services in the United States. Headquartered in New York City, the company operates a growing network of clinics that deliver integrated, patient-centered psychological and psychiatric care. LifeStance’s mission is to expand access to high-quality mental health treatment by combining evidence-based therapy modalities with personalized treatment plans.
The company’s service offerings include individual, family, and group psychotherapy, psychiatric medication management, psychological assessment, and telehealth services.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
